RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
Great news
RT @trishgreenhalgh: Oxford vaccine is safe and generates a good immune response in almost everyone who receives it.
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @MaxCRoser: New results from the Oxford vaccine trial just got published in The Lancet. It studied whether the immune response provoked…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
📌Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial @TheLancet https://t.co/OGZrT6gph6
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
looking good on the single dose inoculation front
RT @JennerInstitute: The Oxford-AstraZeneca #COVID19 #vaccine is safe and immunogenic across age groups
"Older adults (aged ≥70) are at increased risk of severe disease & death if they develop COVID-19 and are therefore a priority for immunisation ....we found similar safety & immunogenicity of ChAdOx1 nCoV-19 in older adults compared with younger ad
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
More good vaccine news 👏👏👏 Go, @SaulFaust @unisouthampton @RDsouthampton @OxfordMedSci https://t.co/gCbmwEx9YL
📍 Buenas noticias. 👏👏👏 👉🏻 La Universidad anuncia resultados positivos en 99% del grupo de voluntarios mayores de 55 años. La vacuna genera alto grado de anticuerpos y células T. #COVID19
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @mark_toshner: For those asking about safety in older populations, hot off press this am from Oxford ChadOx vaccine study- encouraging i…
RT @CrisBonorino: More good news
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @teozka: Resultados de fase 2 de vacuna Oxford/AstraZeneca publicados hoy en Lancet. Al ser fase 2 el estudio de enfoca en inmunogenicid…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @MaxCRoser: New results from the Oxford vaccine trial just got published in The Lancet. It studied whether the immune response provoked…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
👇
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/6lTn6sjhEL
👇
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
A punto la de Oxford 👇
RT @MaxCRoser: New results from the Oxford vaccine trial just got published in The Lancet. It studied whether the immune response provoked…
1. Pfizer 2. Moderna 3. AstraZeneca
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @TheLancet: Authors note that their new findings could be encouraging if the immune responses found in their study are associated with p…
RT @teozka: Resultados de fase 2 de vacuna Oxford/AstraZeneca publicados hoy en Lancet. Al ser fase 2 el estudio de enfoca en inmunogenicid…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @MaxCRoser: New results from the Oxford vaccine trial just got published in The Lancet. It studied whether the immune response provoked…
RT @CathGreenLab: Our paper on immune responses to the oxford AZ vaccine in the elderly is now out. It’s good news. https://t.co/rPIL01AU2L
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
Vacuna de Oxford (Lancet. Ojo, son de la fase II, muestra pequeña... pero al menos no son notas de prensa) => A los 14 días después de la dosis de refuerzo, 208 (> 99%) de los 209 participantes tenían respuestas de anticuerpos neutralizantes". http
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @trishgreenhalgh: Oxford vaccine is safe and generates a good immune response in almost everyone who receives it.
People who make vaccines are just so darn clever!
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @teozka: Resultados de fase 2 de vacuna Oxford/AstraZeneca publicados hoy en Lancet. Al ser fase 2 el estudio de enfoca en inmunogenicid…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @hildabast: Another publication of phase 2 results from the Oxford/AstraZeneca vaccine trial in the UK. https://t.co/yY2020YJhT And it's…
RT @trishgreenhalgh: Oxford vaccine is safe and generates a good immune response in almost everyone who receives it. https://t.co/KcnZmrEeJK
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
Promising, but when will we see the efficiency data?
RT @ProfKatieEwer: Our latest data from @JennerInstitute and @OxfordVacGroup in showing that the Oxford/AZ #COVID19 #vaccine is safe and im…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @prieto_alhambra: Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (CO…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @mark_toshner: For those asking about safety in older populations, hot off press this am from Oxford ChadOx vaccine study- encouraging i…
RT @TheLancet: Authors note that their new findings could be encouraging if the immune responses found in their study are associated with p…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @HannahRSharpe14: Another fantastic result from @JennerInstitute, ChAdOx1 nCoV19 is equally immunogenic in older adults ✨ #COVID19 Cont…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @trishgreenhalgh: Oxford vaccine is safe and generates a good immune response in almost everyone who receives it.
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
Another fantastic result from @JennerInstitute, ChAdOx1 nCoV19 is equally immunogenic in older adults ✨ #COVID19 Continuously amazed by the hard work of my colleagues and grateful to be a part of this effort 👩🏼🔬🔬
RT @trishgreenhalgh: Oxford vaccine is safe and generates a good immune response in almost everyone who receives it.
RT @o_guest: Imagine if we always funded scientific research like this...
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
Phase 2 results of Oxford-AstraZeneca #Covid19 vaccine are encouraging:
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @DrDerekConnolly: The results of the Oxford Jenner Institute COVID Vaccine are stunning ⭐️ ChAdOx1 nCoV-19 appears to be better tolerat…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @MaxCRoser: New results from the Oxford vaccine trial just got published in The Lancet. It studied whether the immune response provoked…
For those asking about safety in older populations, hot off press this am from Oxford ChadOx vaccine study- encouraging immune responses and first safety data in older sub groups https://t.co/LJW9R9VzRh
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
Our Phase 2 results are encouraging and exciting, showing that our vaccine is safe and can produce a good immune response in older adults. https://t.co/ZP5Tyr7nWl